Roche, Prothena Enter Into Worldwide Collaboration to Co-Develop Antibodies for Treatment of Parkinson's Disease

Roche (OTC: RHHBY ) and Prothena Corporation plc (Nasdaq: PRTA ), announced today that they have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease, which is currently in preclinical development and